Ocrelizumab initiation in patients with MS: A multicenter observational study
Conclusions
We provide class IV evidence that treatment with ocrelizumab can stabilize naive and pretreated patients, indicating that ocrelizumab is an option following potent MS drugs such as natalizumab and fingolimod. Further studies are warranted to confirm these findings and to reveal safety concerns in the longer-term follow-up.
Classification of evidence
This study provides Class IV evidence that for patients with MS, ocrelizumab can stabilize both treatment-naive and previously treated patients.
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Ellwardt, E., Rolfes, L., Klein, J., Pape, K., Ruck, T., Wiendl, H., Schroeter, M., Zipp, F., Meuth, S. G., Warnke, C., Bittner, S. Tags: Autoimmune diseases, All Clinical Neurology, Class IV, Multiple sclerosis Article Source Type: research
More News: Autoimmune Disease | Brain | Disability | Gilenya | Multiple Sclerosis | Neurology | Study | Tysabri | Women